Contributions
Type: Publication Only
Background
Multiple myeloma (MM) is a malignant disease characterized by clonal proliferation of plasma cells (PC) and their accumulation in the bone marrow (BM). Cytogenetics alterations have a remarkable prognostic value in patients with MM. But the main limitation of the karyotype study is that PC have a low proliferative index, and conventional cytogenetics methods allow to detect chromosomal alterations in only 20-40% of cases at diagnosis. For this reason the eligible diagnostic technique is the iFISH in selected PC. Selected PC cytogenetics cultures studies are not found in the literature
Aims
To optimize the conventional cytogenetic study by the selection of PC
Methods
In 32 patients with PC neoplasms (19 MM at diagnosis, three MM after treatment, five MM at relapse, three smoldering MM (SMM) and two monoclonal gammopathy of undetermined significance (MGUS)) a PC negative selection with the commercial kit RosetteSep® Human Multiple Myeloma Cell Enrichment Cocktail (Stemcell®) and the culture (SCP) was performed. In parallel, a conventional culture (N-SCP) as a control was performed in 27 patients. To evaluate the technique efficiency, in both cultures, the %CP post-culture and the detection of chromosome alterations were compared
Results
It was observed that the PC negative selection prior to culture significantly increased the %CP post-culture (54% SCP vs 16.9% N-SCP) in all PC neoplasms (p=0.02) and significantly increased the detection of chromosome aberrations (75% SCP vs 37,5% N-SCP) (p=0.022) . It was also confirmed the possibility to perform the iFISH technique in addition to karyotype and the increase in the percentage of interfasic nuclei with genetic alterations in SPC culture(71% SCP vs 16% N-SCP)
Summary
The PC selected culture is a viable, simple and effective technique that allows the conventional cytogenetic study with an increase of chromosomal aberrations detection in patients with PC neoplasms (75%) and also allows iFISH study
Keyword(s): Cytogenetic abnormalities, Multiple myeloma
Type: Publication Only
Background
Multiple myeloma (MM) is a malignant disease characterized by clonal proliferation of plasma cells (PC) and their accumulation in the bone marrow (BM). Cytogenetics alterations have a remarkable prognostic value in patients with MM. But the main limitation of the karyotype study is that PC have a low proliferative index, and conventional cytogenetics methods allow to detect chromosomal alterations in only 20-40% of cases at diagnosis. For this reason the eligible diagnostic technique is the iFISH in selected PC. Selected PC cytogenetics cultures studies are not found in the literature
Aims
To optimize the conventional cytogenetic study by the selection of PC
Methods
In 32 patients with PC neoplasms (19 MM at diagnosis, three MM after treatment, five MM at relapse, three smoldering MM (SMM) and two monoclonal gammopathy of undetermined significance (MGUS)) a PC negative selection with the commercial kit RosetteSep® Human Multiple Myeloma Cell Enrichment Cocktail (Stemcell®) and the culture (SCP) was performed. In parallel, a conventional culture (N-SCP) as a control was performed in 27 patients. To evaluate the technique efficiency, in both cultures, the %CP post-culture and the detection of chromosome alterations were compared
Results
It was observed that the PC negative selection prior to culture significantly increased the %CP post-culture (54% SCP vs 16.9% N-SCP) in all PC neoplasms (p=0.02) and significantly increased the detection of chromosome aberrations (75% SCP vs 37,5% N-SCP) (p=0.022) . It was also confirmed the possibility to perform the iFISH technique in addition to karyotype and the increase in the percentage of interfasic nuclei with genetic alterations in SPC culture(71% SCP vs 16% N-SCP)
Summary
The PC selected culture is a viable, simple and effective technique that allows the conventional cytogenetic study with an increase of chromosomal aberrations detection in patients with PC neoplasms (75%) and also allows iFISH study
Keyword(s): Cytogenetic abnormalities, Multiple myeloma